Naomi Thomas


I graduated from Bristol University in 2004, and worked as a general paediatrician in South Wales and the South East – a broad basis being helpful for a condition as varied and complex as mitochondrial disease. I joined the Newcastle mitochondrial clinical team in 2018; as a Clinical Trials Lead, my focus is delivering and advising upon clinical trials and translational research.

Research Focus

AIMM trial (Acipimox in Mitochondrial Myopathy): Randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in patients with Mitochondrial Myopathy

I am the Principle Investigator for the AIMM trial.  This trial aims to investigate whether acipimox, currently used to manage lipids in patients with diabetes, can treat some of the debilitating muscle problems experienced by patients with mitochondrial disease. The study has closed to recruitment, and we are currently analysing the data in preparation for publication

Other clinical trials I have been or am currently involved with include:

STRIDE: A double-blind, placebo-controlled, study to evaluate the efficacy and safety of 24 weeks treatment with REN001 in patients with primary mitochondrial myopathy (PMM)

MIT-E: Efficacy and Safety Study of Vatiquinone for the Treatment of Refractory Epilepsy in Paediatric Subjects with Mitochondrial Disease

Abliva: A phase Ia/Ib, multiple-site study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of KL1333 after a single and multiple ascending oral doses in healthy subjects and patients with primary mitochondrial disease

Reneo: An open-label study to evaluate the safety and tolerability of 12 weeks treatment with oral REN001 in patients with primary mitochondrial myopathy, with an optional extension of treatment

Khenergyze:  A Phase IIb double-blind, randomised, placebo controlled, multi-centre, confirmative three-way crossover study on cognitive function with two doses of KH176 in subjects with a genetically confirmed mitochondrial tRNALeu(UUR) m.3243A>G mutation

LION: Leigh syndrome: Investigating Outcome measures & Natural history (LION) – a prospective, longitudinal cohort study

Sponsor/Funder: The Newcastle Upon Tyne Hospitals Foundation Trust/Medical Research Council – Developmental Pathway Funding Stream (DPFS)